How should I manage a patient with a lithium serum concentration of 0.2 mEq/L who is taking 450 mg twice daily?

A lithium level of 0.2 mEq/L is subtherapeutic—increase the dose immediately.

Your patient is receiving essentially no therapeutic benefit at this level and requires dose escalation to reach the target range of 0.6-0.8 mEq/L for maintenance therapy 1.

Understanding the Problem

A serum lithium concentration of 0.2 mEq/L on 450 mg twice daily (900 mg/day total) indicates one of several possibilities:

• Non-adherence (most common)
• Extremely rapid renal clearance
• Incorrect timing of blood draw (not a true trough level)
• Laboratory error

The FDA-approved therapeutic range for long-term maintenance is 0.6-1.2 mEq/L, with blood drawn 8-12 hours after the last dose 1. Your patient's level is less than one-third of the minimum therapeutic threshold.

Immediate Action Steps

First, verify the level is accurate:

• Confirm the blood was drawn as a trough (8-12 hours post-dose, immediately before the next scheduled dose) 1
• If timing was incorrect, repeat the level with proper timing
• If timing was correct, directly assess adherence through pill counts or pharmacy refill records

Second, assuming the level is accurate and the patient is adherent:

• Increase the dose to 600 mg three times daily (1800 mg/day total) 1
• The FDA label states that acute mania typically requires 600 mg TID to achieve therapeutic levels of 1.0-1.5 mEq/L, and your patient isn't even reaching maintenance levels on half this dose 1
• Recheck the lithium level in one week (not two weeks—this patient needs closer monitoring given the unexpectedly low level)

Target Therapeutic Range

For maintenance therapy, aim for 0.6-0.8 mEq/L 2, 3. The evidence strongly supports this narrower range rather than the older 0.6-1.2 mEq/L recommendation:

• Levels >0.8 mEq/L show poor tolerability without additional efficacy benefit in most patients 2
• The minimum efficacious level is 0.4 mEq/L, but optimal response occurs at 0.6-0.75 mEq/L 3
• Higher levels (0.7-0.8 mEq/L) are reserved for acute mania or prophylaxis of predominantly manic symptoms 2

Dosing Algorithm

Starting from your current 0.2 mEq/L level:

1. Increase to 600 mg TID (1800 mg/day) as the initial target dose 1
2. Check level in 5-7 days (steady state is reached in approximately 5 days given lithium's 18-36 hour half-life) 4
3. If level remains <0.6 mEq/L, increase by 300-600 mg/day increments
4. Once in therapeutic range (0.6-0.8 mEq/L), monitor every 2 weeks until stable, then every 2 months 1

Critical Monitoring Considerations

Watch for factors that could explain the low level:

• Renal function: High GFR increases lithium clearance 4
• Age: Younger patients (<40 years) typically require 925-1300 mg/day for maintenance 4
• Drug interactions: NSAIDs, ACE inhibitors, and diuretics increase lithium levels (not relevant here, but important when levels rise) 2, 5

Avoid abrupt level changes: Once therapeutic, do not allow serum levels to drop by >0.2 mmol/L suddenly, as this increases relapse risk 3. This is not relevant now since the patient is subtherapeutic, but becomes critical once you achieve target levels.

Common Pitfalls

• Don't accept 0.4-0.6 mEq/L as "good enough": While 0.4 mEq/L shows some efficacy, optimal response requires 0.6-0.75 mEq/L 3
• Don't assume the patient is a "low-dose responder": At 0.2 mEq/L, there is insufficient lithium to exert meaningful mood stabilization
• Don't increase too slowly: This patient needs aggressive dose escalation given how far below target they are
• Don't forget to assess adherence: A level this low on 900 mg/day strongly suggests non-adherence unless the patient has exceptional renal clearance

Special Population Adjustments

If your patient is >50 years old, target the lower end of the therapeutic range (0.5-0.6 mEq/L) due to increased sensitivity and toxicity risk 2. However, they still need to reach at least 0.5 mEq/L to derive benefit.

If the patient has renal impairment, diabetes insipidus, thyroid dysfunction, or takes diuretics/ACE inhibitors/NSAIDs, also target 0.5-0.6 mEq/L 2. The FDA label notes that lithium should generally not be given to patients with significant renal disease due to high toxicity risk 1.

Your patient at 0.2 mEq/L is essentially untreated—escalate the dose to 1800 mg/day and recheck the level in one week.